Authorization of anastrazole to prevent breast cancer in postmenopausal women: a bad idea

Anastrazole has recently been approved for the prevention of breast cancer in high-risk women in the UK. When given to high-risk women anastrazole halves the risk of developing breast cancer but doesn't reduce the risk of breast cancer death and is associated with significant harms. Women need...

Full description

Saved in:
Bibliographic Details
Published in:Climacteric : the journal of the International Menopause Society 2024-04, Vol.27 (2), p.1-216
Main Authors: Glynne, S J, Bluming, A Z
Format: Article
Language:English
Subjects:
Breast cancer
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Anastrazole has recently been approved for the prevention of breast cancer in high-risk women in the UK. When given to high-risk women anastrazole halves the risk of developing breast cancer but doesn't reduce the risk of breast cancer death and is associated with significant harms. Women need to be counselled about both the benefits and risks associated with anastrazole use to enable an informed treatment choice.
ISSN:1369-7137
1473-0804
DOI:10.1080/13697137.2023.2297889